FindTrial
Sign In

Omics reveal heterogeneity in the efficacy of targeted drug therapy in axial spondyloarthritis and construct predictive models

Omics reveal heterogeneity in the efficacy of targeted drug therapy in axial spondyloarthritis and construct predictive models

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500105344
Enrollment
Unknown
Registered
2025-07-02
Start date
2025-07-15
Completion date
Unknown
Last updated
2025-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Axial Spondyloarthritis

Interventions

TNFa antagonist group:None
IL-17A inhibitor group:None
JAK inhibitor group:None

Sponsors

The First Affiliated Hospital of Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) or Bath Ankylosing Spondylitis Functional Index (BASFI) score of >4 in patients with axSpA, or failure of NSAIDs therapy: at least two different kinds of treatment for more than 4 weeks without response or intolerance, each of which is the maximum therapeutic dose that can be tolerated; 2. Eligible for NSAIDS and/or sulfasalazine, excluding targeted drugs, glucocorticoids or methotrexate and other DMARDs; 3. Intended to receive targeted drug therapy for the first time.

Exclusion criteria

Exclusion criteria: Age <18 years or inability to undergo MRI examination

Design outcomes

Primary

MeasureTime frame
MRI SPARCC score;Radiomic features;—

Secondary

MeasureTime frame
ASDAS-CRP;ASDAS-ESR;Bath Ankylosing Spondylitis Functional Index;Bath Ankylosing Spondylitis Disease Activity Index;—

Countries

China

Contacts

Public ContactLusi Ye

The First Affiliated Hospital of Wenzhou Medical University

yelusi@hotmail.com+86 137 5789 4089

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026